Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Diminished Expectations For Insulin Biosimilar Market Likely Scuttled Partnership With Biocon

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer and India’s Biocon called off their four-product diabetes biosimilar partnership on March 12, with Biocon keeping more than $100 million realized over the life of the deal and regaining all product IP.

You may also be interested in...



Armed With A Range Of Insulins, Pfizer Is Weeks Away From Its First Biosimilars Rollout In India - BIO 2011 Conference

WASHINGTON - Pfizer Inc. is all set to kick-off its journey into the world of biosimilars as it gives finishing touches to the launch of a range of insulins in India. The company is counting on a set of value propositions, high quality and competitive pricing to emerge as a "natural leader" in the Indian market

With Biocon Deal, Pfizer Expects To Gain First Mover Advantage In Global Biosimilar Insulin Market

MUMBAI - Months of widespread speculation over a likely deal between Pfizer and India's biotechnology flag-bearer Biocon finally came true as the two companies announced a comprehensive global commercialization pact to bring to market a range of insulins including analogs like glargine, aspart and lispro

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS073875

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel